Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-HBs
- Development stage
- Unknown
- Lead developer
- Oxford BioMedica
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
MVA-HBs is a recombinant viral vector therapeutic vaccine designed for the treatment of chronic hepatitis B virus (HBV) infection. It utilizes the Modified Vaccinia virus Ankara (MVA) platform, a highly attenuated poxvirus, to deliver and express the HBV surface antigen (HBsAg). Developed by the Centre for Clinical Vaccinology and Tropical Medicine at the University of Oxford, the vaccine is typically employed as the booster component in a heterologous prime-boost strategy, following priming with a DNA plasmid vaccine (such as pSG2.HBs). The primary goal of MVA-HBs is to stimulate a robust, T-cell-mediated immune response against HBsAg to overcome the immune tolerance characteristic of chronic HBV infection. Clinical trials have evaluated its safety and immunogenicity in healthy volunteers and HBe antigen-negative chronic HBV carriers, sometimes in combination with the antiviral drug lamivudine.
- Other names
- MVA-HBsAgMVA-vectored HBV vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on MVA-HBs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-HBs.